Denys-Drash Syndrome (DDS)Symptoms, Doctors, Treatments, Advances & More
Denys-Drash Syndrome (DDS) Overview
Learn About Denys-Drash Syndrome (DDS)
Denys-Drash syndrome is a condition that affects the kidneys and genitalia.
Mutations in the WT1 gene cause Denys-Drash syndrome. The WT1 gene provides instructions for making a protein that regulates the activity of other genes by attaching (binding) to specific regions of DNA. On the basis of this action, the WT1 protein is called a transcription factor. The WT1 protein plays a role in the development of the kidneys and gonads (ovaries in females and testes in males) before birth.
The prevalence of Denys-Drash syndrome is unknown; at least 150 affected individuals have been reported in the scientific literature.
This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.
Sorahia Domenice practices practicing medicine in Sao Paulo, Brazil. Domenice is rated as an Elite expert by MediFind in the treatment of Denys-Drash Syndrome (DDS). They are also highly rated in 14 other conditions, according to our data. Their clinical expertise encompasses Intersex, Partial Androgen Insensitivity Syndrome (PAIS), Denys-Drash Syndrome (DDS), Turner Syndrome, and Hormone Replacement Therapy (HRT).
Nephrology & Hypertension Specialists PC
Rafael Duchesne is a Nephrologist practicing medicine in Dalton, Georgia. Dr. Duchesne is rated as a Distinguished provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Renovascular Hypertension, End-Stage Renal Disease (ESRD), Chronic Kidney Disease, and Acute Kidney Failure. Dr. Duchesne is currently accepting new patients.
Regional Kidney Care
Steven Butler is a Nephrologist practicing medicine in Kingsport, Tennessee. Dr. Butler is rated as an Advanced provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses End-Stage Renal Disease (ESRD), Chronic Kidney Disease, Acute Kidney Failure, and Nephrosclerosis. Dr. Butler is board certified in American Board Of Internal Medicine. Dr. Butler is currently accepting new patients.
Summary: This phase I/II trial studies the effects of trastuzumab deruxtecan (DS-8201a) in treating patients with osteosarcoma, Wilms tumor (WT) or desmoplastic small round cell tumor (DSRCT) that is newly diagnosed or has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Trastuzumab deruxtecan is in a class of medications called antibody-drug...
Summary: This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide...
Published Date: March 01, 2013
Published By: National Institutes of Health